Literature DB >> 24927333

Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.

Katharina Leuchte1, Bianca Altvater1, Simeon Hoffschlag1, Jenny Potratz1, Jutta Meltzer1, Dagmar Clemens1, Andrea Luecke1, Jendrik Hardes2, Uta Dirksen1, Heribert Juergens1, Sareetha Kailayangiri1, Claudia Rossig1.   

Abstract

Novel treatment strategies for Ewing sarcoma aim to eliminate residual tumor cells that have maintained the capacity to reinitiate tumor growth after intensive conventional therapy. Preclinical models that more closely mimic in vivo tumor growth than standard monolayer cultures are needed. Sphere formation under anchorage-independent, serum-free conditions has been proposed to enrich for cells with tumor-initiating, stem cell-like properties in various solid cancers. In the present study, we assessed the phenotype and functional stem cell characteristics of Ewing sarcoma spheres. Spheres were generated under serum-free culture conditions from four Ewing sarcoma cell lines and four relapse tumor biopsies. Standard monolayer cultures were established as controls. Median levels of surface expression of the Ewing sarcoma marker CD99 as well as the supposed stem cell marker CD133 and the neural crest marker CD57 were comparable between spheres and monolayers. Ewing sarcoma spheres from individual tumors failed to continuously self-renew by secondary sphere formation. They contained variable proportions of side populations (SPs). Sphere culture did not enhance the in vivo tumorigenicity of Ewing sarcoma cells in a murine xenograft model. We conclude that sphere formation under serum-free conditions is not a reliable tool to enrich for cells with stem cell characteristics in Ewing sarcoma. By mimicking the anchorage-independent, multicellular growth of Ewing sarcoma micrometastases, in vitro sphere growth may still add value as a preclinical tool to evaluate the efficacy of novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927333     DOI: 10.3892/or.2014.3269

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

2.  EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Stefanie Lesch; Sebastian Balbach; Claudia Göttlich; Johanna Kühnemundt; Jan-Henrik Mikesch; Sonja Schelhaas; Silke Jamitzky; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Kornelius Kerl; Holger N Lode; Nikolai Siebert; Ingo Müller; Heike Walles; Wolfgang Hartmann; Claudia Rossig
Journal:  Mol Ther       Date:  2019-02-23       Impact factor: 11.454

3.  Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.

Authors:  Bárbara Kunzler Souza; Patrícia Luciana da Costa Lopez; Pâmela Rossi Menegotto; Igor Araujo Vieira; Nathalia Kersting; Ana Lúcia Abujamra; André T Brunetto; Algemir L Brunetto; Lauro Gregianin; Caroline Brunetto de Farias; Carol J Thiele; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

Review 4.  In vitro three-dimensional cell cultures for bone sarcomas.

Authors:  Javier Munoz-Garcia; Camille Jubelin; Aurélie Loussouarn; Matisse Goumard; Laurent Griscom; Axelle Renodon-Cornière; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2021-07-06       Impact factor: 4.072

Review 5.  Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells.

Authors:  Tomohiro Fujiwara; Toshifumi Ozaki
Journal:  Stem Cells Int       Date:  2016-12-27       Impact factor: 5.443

6.  Pediatric sarcomas.

Authors:  Junhua Cao; Qi An; Lei Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

7.  Splice variants denote differences between a cancer stem cell side population of EWSR1‑ERG‑based Ewing sarcoma cells, its main population and EWSR1‑FLI‑based cells.

Authors:  Eberhard Korsching; Julian Matschke; Marc Hotfilder
Journal:  Int J Mol Med       Date:  2022-01-28       Impact factor: 4.101

8.  The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.

Authors:  Philipp Berning; Christiane Schaefer; Dagmar Clemens; Eberhard Korsching; Uta Dirksen; Jenny Potratz
Journal:  Cell Commun Signal       Date:  2018-05-18       Impact factor: 5.712

Review 9.  Modeling neoplastic disease with spheroids and organoids.

Authors:  Michele Zanoni; Michela Cortesi; Alice Zamagni; Chiara Arienti; Sara Pignatta; Anna Tesei
Journal:  J Hematol Oncol       Date:  2020-07-16       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.